Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Tricida Inc. (NASDAQ:TCDA)

Organization & Developments: Tricida

Parents

2020: FDA Rejects Tricida Chronic Kidney Disease Drug, More Data Needed
2022: First came the news of strategic review. Now Tricida is letting more than half of its staff go in wake of PhIII flop
2022: More biotechs hit the wall as Rubius lays off 82% of staff and Tricida seeks a sale_
2022: Tricida to lay off ~60% of employees following strategic review announcement_seekingalpha.com
2022: Tricida: Important Binary Event Coming Up_seekingalpha.com
2022: Tricida’s shares plunge as phase 3 fail seals fate of FDA-rejected kidney disease drug
A micro-cap pharmaceutical company developing veverimer (TRC-101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI) tract.